Anti-CD20 CAR-T cell therapy (Beijing Biohealthcare Biotechnology)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAnti-CD20 CAR-T cell therapy (Beijing Biohealthcare Biotechnology)
Drug Alias NameAnti-CD20 CAR-T cell therapy - Beijing Biohealthcare Biotechnology
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsStomach NeoplasmsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesBeijing Biohealthcare Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeijing Biohealthcare Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsStomach NeoplasmsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A